Skip to content

Study · Randomized controlled trial · 2017

4 results

Effects of DPP-4 inhibitor linagliptin and GLP-1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open-label, 2-arm parallel comparative, exploratory trial.

Yabe D, Eto T, Shiramoto M, Irie S, Murotani K, Seino Y, Kuwata H, Kurose T, Seino S, Ahrén B, Seino Y

Diabetes, obesity & metabolism29 Nov 2016Cited by 26 (Europe PMC)

PMID27800649 (opens in a new tab)PMCIDPMC5347937 (opens in a new tab)DOI10.1111/dom.12817 (opens in a new tab)PepBankPUB-27800649
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes, the rise in glucagon during the hypoglycaemic clamp at 2.5 mmol/L was similar with liraglutide and linagliptin, before and after 2 weeks of treatment.

    In plain wordsIn Japanese people with type 2 diabetes, the glucagon rise during low blood sugar was similar with liraglutide and with linagliptin.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlucagon response during hypoglycaemic clamp, liraglutide versus linagliptin
    Study

    n: not reported in source

    Comparator
    Linagliptin
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Glucagon levels were increased during the hypoglycaemic clamp test at 2.5 mmol/L. This increase was similar in the linagliptin and liraglutide groups, both before and after the 2-week treatment.
    2 context sentences
    Summary · context
    To examine this model in Japanese individuals with type 2 diabetes (T2D), the effects of the DPP-4 inhibitor linagliptin on glucagon and other counter-regulatory hormone responses to hypoglycaemia were evaluated and compared with those of the GLP-1 receptor agonist liraglutide in a multi-centre, ran…
    Summary · context
    Three-step hypoglycaemic clamp glucose tests preceded by meal tolerance tests were performed before and after 2-week treatment with the drugs.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes, the glucagon response to hypoglycaemia was not affected by 2 weeks of liraglutide treatment.

    In plain wordsIn Japanese people with type 2 diabetes, liraglutide did not change the glucagon response to low blood sugar.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlucagon response to hypoglycaemia after liraglutide treatment
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    In conclusion, we confirmed that the glucagon response to hypoglycaemia was not affected by linagliptin or liraglutide treatment in Japanese individuals with T2D.
    2 context sentences
    Summary · context
    To examine this model in Japanese individuals with type 2 diabetes (T2D), the effects of the DPP-4 inhibitor linagliptin on glucagon and other counter-regulatory hormone responses to hypoglycaemia were evaluated and compared with those of the GLP-1 receptor agonist liraglutide in a multi-centre, ran…
    Summary · context
    Three-step hypoglycaemic clamp glucose tests preceded by meal tolerance tests were performed before and after 2-week treatment with the drugs.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes, changes in growth hormone, cortisol, epinephrine and norepinephrine during hypoglycaemia were similar between the liraglutide and linagliptin groups.

    In plain wordsIn Japanese people with type 2 diabetes, other stress hormone changes during low blood sugar were similar with liraglutide and with linagliptin.

    Peptide
    Liraglutide
    Outcome
    No significant changeOther counter-regulatory hormone responses (growth hormone, cortisol, epinephrine, norepinephrine), liraglutide versus linagliptin
    Study

    n: not reported in source

    Comparator
    Linagliptin
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    Changes in other counter-regulatory hormones (ie, growth hormone, cortisol, epinephrine and norepinephrine) were also similar between the groups
    2 context sentences
    Summary · context
    To examine this model in Japanese individuals with type 2 diabetes (T2D), the effects of the DPP-4 inhibitor linagliptin on glucagon and other counter-regulatory hormone responses to hypoglycaemia were evaluated and compared with those of the GLP-1 receptor agonist liraglutide in a multi-centre, ran…
    Summary · context
    Three-step hypoglycaemic clamp glucose tests preceded by meal tolerance tests were performed before and after 2-week treatment with the drugs.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Japanese adults with type 2 diabetes, other counter-regulatory hormone responses to hypoglycaemia were substantially suppressed after 2 weeks of treatment compared with baseline, in both the liraglutide and linagliptin groups.

    In plain wordsIn Japanese people with type 2 diabetes, other stress hormone responses to low blood sugar were lower after 2 weeks than at baseline.

    Peptide
    Liraglutide
    Outcome
    DecreaseOther counter-regulatory hormone responses after 2 weeks versus baseline
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Hormone levels · Endocrine and hormones
    Studied dose
    Dose not stated · 2 weeksAs given in this study (human).

    Source sentences

    Summary
    but were suppressed substantially after 2-week treatment compared to baseline.
    2 context sentences
    Summary · context
    To examine this model in Japanese individuals with type 2 diabetes (T2D), the effects of the DPP-4 inhibitor linagliptin on glucagon and other counter-regulatory hormone responses to hypoglycaemia were evaluated and compared with those of the GLP-1 receptor agonist liraglutide in a multi-centre, ran…
    Summary · context
    Three-step hypoglycaemic clamp glucose tests preceded by meal tolerance tests were performed before and after 2-week treatment with the drugs.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.